Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

Analysis published in the journal Blood found 92 percent reduction in

incidence of thromboses

CHESHIRE, Conn., Aug. 20 /PRNewswire-FirstCall/ -- Patients with a rare blood disorder called PNH experienced a 92 percent reduction in the incidence of life-threatening blood clots (thromboses) following treatment with Soliris(TM) (eculizumab), according to an analysis of clinical studies recently published online in Blood, the journal of the American Society of Hematology.

Soliris, developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), is the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can cause severe anemia, disabling fatigue, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), kidney disease, impaired quality of life and thromboses. (1,2)

"Thrombosis is the leading cause of premature death in PNH patients and the most feared complication of PNH," said Dr. Peter Hillmen, senior author of the paper and Consultant Haematologist of the General Infirmary at Leeds, Leeds, UK. "In several clinical trials, Soliris reduced hemolysis in all PNH patients and significantly improved anemia, fatigue and quality of life. The comprehensive analyses demonstrate that Soliris substantially reduced the risk of thrombosis in a diverse population of PNH patients, including those who might be expected to have less severe disease."

Approximately 40 percent of patients with PNH experience thrombosis during the course of the disease.(3,4,5,6) An ini
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Leading events organizer UBM Live announces that ... year to São Paulo, Brazil from ... event will co-locate with Food Ingredients South America (FiSA), creating ... for the pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... are now exploring the South America ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... 19, 2007 - Acorda,Therapeutics (Nasdaq: ACOR) today announced ... Center at the University,of Rochester, will present data ... in multiple sclerosis at the,upcoming American Academy of ... on Wednesday May 2, 2007 at 4:15 pm,Eastern ...
... Full Study Results,to Be Presented at the American ... ,WIRE) -- 03/19/2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) ... of its lead drug,candidate, AGI-1067, did not show ... however, it did achieve a number of,other important ...
Cached Medicine Technology:Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting 2AtheroGenics Reports ARISE Trial Results for AGI-1067 2AtheroGenics Reports ARISE Trial Results for AGI-1067 3AtheroGenics Reports ARISE Trial Results for AGI-1067 4
(Date:7/26/2014)... 2014 According to the ... Vkool.com, this is a comprehensive guide that ... treating all types of disorders related ...     Tinnitus due to Ménière's disease , ... pathway tinnitus ,     Inner, middle or ...
(Date:7/26/2014)... July 26, 2014 Studio B Dental in ... implant, often called Teeth in a Day, gives patients the ... full set of bright, pearly whites with very little recovery ... permanent, look and feel just like natural teeth, and require ... checkups. Studio B Dental is one of the premiere ...
(Date:7/26/2014)... 26, 2014 According to the Metabolic ... is a comprehensive bodybuilding program that helps men lose ... anabolic steroids . The program also instructs men how ... , Vkool reveals in its review that this ... can help men get ripped and jacked at the ...
(Date:7/26/2014)... July 26, 2014 The birth control ... Mirena IUD contraceptive of new legal information on the ... showing the number of lawsuits pending for July alleging ... free resource for those using popular prescription drugs and ... recalls, studies and legal news all in one place, ...
(Date:7/25/2014)... 2014 Deep Research Report on ... Industry” is a professional and in-depth research report ... market. The report provides basic Laser Scanning Confocal ... definition, classification, application, and industry chain structure ... international market analysis, including China’s domestic market as ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4
... (HealthDay News) -- Statin drugs commonly used to lower ... the prostate in men with elevated blood levels of ... Prostate-specific antigen, or PSA, levels are often elevated due ... researchers from Duke University Medical Center in Durham, N.C. ...
... CHAPEL HILL, N.C. Multiple research projects including ... Carolina at Chapel Hill have used DNA microarray ... A, luminal B, basal-like and HER2-enriched. Simple tests are ... to treat their patients in a more biologically-based way. ...
... Diego, CA (May 21, 2012) Each year, ... for their outstanding contributions and achievements in gastroenterology ... award recipients are individuals who have been nominated ... of esteem and confidence from their colleagues. These ...
... Reinberg HealthDay Reporter , SUNDAY, May 20 (HealthDay ... cancer might save the lives of patients at the greatest ... the risks of screening for others aren,t clear, the researchers ... hard to weigh and estimate," said lead researcher Dr. Peter ...
... adolescents with no symptoms of heart disease already have heart ... at the Heart Failure Congress 2012 , 19-22 May, ... of the Heart Failure Association of the European Society of ... disease, and previous research has shown that obese adults have ...
... , FRIDAY, May 18 (HealthDay News) -- Women who eat ... brain function and memory over time, Harvard University researchers report. ... function and memory, suggesting that fats may have the same ... the researchers added. "Making changes and substitutions in one,s ...
Cached Medicine News:Health News:Statins May Help Prevent Enlarged Prostate: Study 2Health News:Statins May Help Prevent Enlarged Prostate: Study 3Health News:Discovery suggests new combination therapy strategy for basal-like breast cancers 2Health News:AGA announces prestigious awards recognition recipients 2Health News:AGA announces prestigious awards recognition recipients 3Health News:Screening for Lung Cancer Might Benefit Those at Highest Risk 2Health News:Screening for Lung Cancer Might Benefit Those at Highest Risk 3Health News:Obese adolescents have heart damage 2Health News:'Bad' Fat May Hurt Brain Function Over Time 2Health News:'Bad' Fat May Hurt Brain Function Over Time 3
18" Penrose drains...
Provides reliable suction for surgical cases with larger amounts of drainage....
Reliavac® 400cc kits with silicone round drain with 10 in. hole pattern, trocar, and Y-connector tubing...
Reliavac® 100cc medium suction evacuator kits with flat drains and Y-connector tubing...
Medicine Products: